ADAR1 Capital Management »

Nurix Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Nurix Therapeutics (NRIX) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Nurix Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Nurix Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Nurix Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $523k 36k 14.70

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Nurix Therapeutics

BlackRock
BlackRock
Redmile Group
Deep Track Capital
Baker Bros. Advisors
Vanguard Group
T. Rowe Price Associates
State Street Corporation
T. Rowe Price Investment Management
ARK Investment Management
Soleus Capital Management
Morgan Stanley
Pictet Asset Management Holding SA
Commodore Capital
Citadel Advisors

View all funds holding Nurix Therapeutics